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Abstract 
Background: The regenerative effectiveness of lipoaspirate procedures relies on the presence of 
mesenchymal stem cells, but the stromal microenvironment and hormonal secretions of the 
adipose tissue may be involved in cancer growth. Only few oncological outcome studies of fat 
grafting at the surgical site of malignant neoplasms of mesenchymal origin are available; none of 
these studies examined a series of sarcoma cases. Objectives: We analyzed outcome in terms of 
local or distant spread and overall survival to investigate the oncological safety of fat grafting in 
patients with sarcoma. Patients and methods: Sixty consecutive patients who had undergone 143 
fat grafting procedures after surgical resection of bone and soft tissue sarcomas of the head, 
trunk, and limbs with clear resection margins were enrolled from 2004 to 2015 in our tertiary 
care center. A mul- tidisciplinary sarcoma team administered adjuvant therapies. Patients were 
recurrence free at fat grafting. Results: The overall median follow-up was 7.5 years. At follow-
up after fat grafting (2.4 years), one patient had distant metastasis and two had local relapse. 
Kaplan–Meier analysis showed disease-free survival rate of 95.4% (CI: 89.1–100.0) at 24 
months. The risk of local recurrence (LR) within 24 months was 4.6% (CI: 0.0–20.9). The 
probability of not having LR after fat grafting was ≥89.1%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
Bone and soft tissue sarcomas form a heterogeneous group of malignant neoplasms of 
mesenchymal origin accounting for 1% of all cancers. 1 They comprise approximately 50 
different types with different clinical behaviors and diverse, often unclear etiologies. The soft 
tissue sarcoma incidence rate is 2.4 per 100,000 per year in the general population, 2 whereas 
bone sarcomas are approximately three times less frequent. Sarcomas affect all age groups but 
are more prevalent in people aged above 55 years. The main primary sites are the extremities 
(50–60%), especially the legs, 3 followed by the trunk, retroperitoneum, breast, and head and 
neck. Radiation-induced soft tissue sarcomas are rare (3% of soft tissue sarcomas) and occur in 
the lung, esophagus, and breast, especially after Hodgkin lymphoma and breast cancer. 4 
Sarcomas can range from low-high-grade malignancy and may be associated with skip 
metastases. Lymph node metastases are rare (10%), except for the synovial type (25%). Distant 
metastases often occur in the lungs. The prognosis and treatment strategies depend on the 
histological type and grade and focus on early diagnosis, compartment surgery, and radiation 
therapy. 5 Chemotherapy may also be used. Disease-specific survival rate is approximately 75%. 
6,7 The local recurrence (LR) rate ranges from 4% to 39% at 5 years, depending on various 
factors. 6–9 Resection with wide tumor- free margins is mandatory for a good prognosis. 
Radiation-induced sarcoma arises sporadically after an average latency period of 10 years and is 
particularly aggressive. Microscopically negative resection margins are difficult to achieve, and 
the LR rate is high, up to 65%. 10 The 5 year overall survival rate has been reported to be 41–
59%. 11,12 Currently, radical tumor resection does not necessarily involve morphological 
alteration and function loss because of reconstructive surgery with autologous flaps, tissue ex- 
panders, nerve and tendon transfers, and, most recently, lipofilling. Fat grafting (lipofilling) was 
repopularized at the turn of the century after the introduction of micro-fat-grafting and 
lipoaspirate-processing techniques. 13,14 The effectiveness of lipoaspirate grafting relies on the 
presence of mesenchymal stem cells and their regenerative effect on extensive scarring or 
radiation damage of the skin and soft tissues. 15 These mesenchymal progenitors of adipocytes 
secrete adipokines, angiogenic cytokines, and growth factors. Importantly, the number of stem 
cells in the lipoaspirate is much higher than that in the bone marrow. 16 The multilineage 
differentiation capacity of adult stem cells is well known. 17 In breast cancer, the stromal 
microenvironment with stromal cells and an adipose context of endocrine autocrine, paracrine, 
and exocrine secretions can contribute to cancer development, recurrence, and metastasis, but 
there is no evidence that stem cells are directly tumorigenic, i.e., able to induce the neoplastic 
transformation of normal cells. 18–20 Evidence of the oncological safety of fat grafting after 
cancer surgery is based primarily on clinical studies in breast cancer and is limited by possible 
bias. Fat injection after mastectomy appears to be safe, but the correction of con- tour defects 
after conservative treatment of the breast re- mains controversial. 21–24 The biology of sarcoma is 
quite different from that of breast carcinoma. The unclear and multifarious etiopathogenesis of 
sarcomas and the high risk of LR combined with the variable signaling of the fat 
microenvironment including adipose-derived stem cells and related growth factors should be 
investigated more extensively. Additionally, plastic surgeons should be aware of potential safety 
issues as these new microenvironments of fat are injected into a surgical bed where dormant 
neoplastic cells can survive even after correct cancer treatment. Unfortunately, reports of patients 
with sarcoma treated by fat grafting are anecdotal. Perrot et al. 25 reported an unexpected local 
osteosarcoma recurrence 13 years after primary cancer treatment and 28–18 months after three 
sets of fat injection. This finding prompted the authors to investigate the behavior of 
mesenchymal stem cells from the human adipose tissue by injecting them in a murine model of 
human osteosarcoma. Their preclinical models showed that fat grafts or progenitor cells can 
promote tumor growth. The purpose of the present study was to analyze the oncological outcome 
after a series of 143 fat-grafting procedures at the surgical sites of former sarcoma resections. All 
patients in this study had presented with soft tissue and bone sarcomas. They were treated and 
followed for a 30 year period at our institute, one of the largest tertiary care sarcoma centers in 
Europe. We reported LRs, distant metastases, and overall survival of these patients after curative 
cancer treatment and investigated in particular the relationship between fat grafting and the risk 
of LR. 
 
Patients and methods 
Sixty-five patients who had undergone fat grafting between June 2004 and April 2015 to restore 
soft tissue defects af- ter resection of primary or recurrent sarcoma were con- sidered for 
inclusion in a consecutive series. Clinical data were extracted from clinical charts, prospective 
databases, and patients’ consultation reports. We excluded one patient because of poor data 
quality and four patients because of the absence of follow-up data. The remaining 60 patients, for 
a total of 143 fat-grafting procedures (mean 2.38 per patient), were included in the study. They 
had undergone surgery for localized sarcoma between 1974 and 2011. The median age at disease 
presentation was 31.7 ±17.9 years (range, 4 months to 66.9 years). The time of primary surgery 
was unknown in three cases. The tumor sites were maxillo- facial (10), head (3), limbs (17), 
trunk (18), breast (10), vagina (1), and perineal/anal area (1). In 18 cases, a surgical biopsy or 
partial excision had been carried out in the months before the major surgery. Tumor-free margins 
had been obtained in all cases. The series included only 25 out of more than 50 forms of 
sarcoma. Table 1 presents the histological types and their frequency. Twenty-three tumors were 
of low-grade malignancy, and 20 were of high-grade malignancy; grading was unknown in the 
earliest cases. The American Joint Committee on Cancer (AJCC) stage of dis- ease 26 at 
presentation to our institution, before fat grafting, was stage I in 19, stage II in 21, and stage III 
in three, and indefinite in the remaining 17 cases but with the exclusion of stage IV. There was 
only one lymph node metastasis in a supraclavicular node at first presentation in a child with a 
thoracic neuroblastoma. Surgery was supplemented with chemotherapy in 34 patients (56.6%) 
and radiotherapy (45–70 Gy) in 35 patients (58.3%). Head, limb, and breast resections were 
followed by plastic reconstructions, and limb-sparing techniques were used in primary surgery. 
In one case, limb hyper- thermic chemoperfusion was applied. The decision about chemotherapy 
and/or radiation was made by a multidisci- plinary sarcoma team or as part of ongoing clinical 
trials and varied during the long course of the study. 
 
Surgical procedure  
Fat grafting was performed after surgical resection with clear resection margins and adjuvant 
therapies according to tumor histology, patient age, and disease stage. The patients’ mean age at 
first or only procedure was 38.8 ±15.0 years (range, 13.9–71.7 years). Fat was harvested by as- 
piration using a 3 mm cannula. The mean volume was 108 ±76.9 cc (range, 12–440 cc); after 
Coleman’s centrifu- gation 14 , the injected fat had a volume of 64.8 ±45.9 cc (range, 3–180 cc). 
The fat amounts were measured in 107 of 143 procedures. 
 
Results 
The mean oncological follow-up time was more than 10 years, ranging from 19.6 months to 
approximately 40 years. The overall median follow-up time was 7.5 years. The median time 
before fat grafting was 3.9 years (range: 0.4–36.5); in this period, the disease-free survival rate 
was 80%: two patients had a single metastasis (one supraclavicular node and one pleural node 
treated by metastasectomy) and 10 patients had LR (16.6%) ( Table 2 ). The median disease- free 
interval before LR was 34 months. Only three patients had multiple LRs (two to five times). One 
thigh amputation was necessary owing to recurrent disease. The median disease-free time from 
LR to fat grating was 52 months. Our study focused on LR after fat grafting, i.e., after the first or 
only procedure. The observation time from fat graft- ing to LR or last follow-up ranged from 2.2 
to 85.5 months (7.1 years), with a median of 28.6 months (2.4 years). Dur- ing this period, LR 
after fat injection was recorded in two patients ( Table 3 ). In the first patient (affected by a 
desmoid tumor, an aggressive soft tissue sarcoma of the extremities), the onset of LR was 
immediate and multiple, at 2.4 and 14 months; in the second patient (with Ewing’s sarcoma) LR 
occurred at 23.4 months. The first patient had a history of LR before fat grafting; the second 
patient had a disease- free interval of 168 months after primary cancer treatment. Only one 
distant relapse was recorded (lung metastasis with death 2 years after fat grafting). The series 
does not report exitus not-related to sarcoma-specific mortality. The overall disease-free survival 
rate was 80% in the period preceding fat grafting and decreased in the years after fat grafting. In 
fact, the overall disease-free survival was 76.6% along all the 7.5 years of total median follow-
up. 
 
Statistical analysis 
Descriptive statistics were reported as median (range) or as the percentage of patients with the 
characteristics. Because of the small number of patients developing LR ( n = 2) and the relatively 
limited follow-up time, Kaplan–Meier analysis of the survival probability was the best option to 
assess the risk of LR following fat grafting after sarcoma surgery. Based on the observed results, 
the survival probability estimates were assessed for a maximum of 24 months. The diagram in 
Figure 1 depicts the estimates of the disease-free survival function with 95% confidence intervals 
(CIs). At 24 months, the value of the survival function was 95.4% (CI 89.1–100.0). This means 
that the probability of not having LR after fat grafting was significantly higher than 89.1%. 
Conversely, the risk of LR within 24 months was 4.6% (CI 0.0–20.9). 
 
Discussion 
Soft tissue sarcomas of the trunk, limbs, and breast were the most common in our study 
population. The disease-free survival rate was 80% at 4 years after surgical resection (be- fore fat 
grafting) and 75% in the entire period of 7.5 years. In a Kaplan–Meier analysis of 543 sarcomas 
of the trunk reported by Wilder et al., 27 the disease-specific survival after surgery was 83% at 5 
years and 74% at 10 years. The recurrence rates after resection were significantly worse for 
patients with breast and chest wall tumors: 5 years after surgery, LR had occurred in 21% of 
patients with breast tumors and 23% of patients with chest wall tumors. At our own institution, 
Gronchi et al. 7 observed a series of 1094 adult patients who were treated for localized soft tissue 
sarcomas of the extremities for a period of 20 years with a median follow-up time of 81 months; 
they found that the 5 year LR rate and cause-specific death incidence declined from 15% and 
23% in the period 1987–1992 to 6% and 9%, respectively, in the period 2003–2007. In the latter 
period, preoperative combined chemoradiation therapy was introduced and administered to 12% 
of patients. The authors considered competitive risks, but their crude cumulative incidence is not 
directly comparable with the probability of LR after fat grafting estimated by us. The disease-
specific survival rate after lipofilling in the present study was 95.4%, and only one sarcoma-
specific death occurred. The exclusion of patients with a dismal prognosis and distant metastases 
as candidates for lipofilling may explain the low mortality. The mortality, and probably also the 
risk of recurrent disease, is low in our study population because the treated patients were free 
from dis- ease at the time of selection for fat grafting. Distant metastases (pleuropulmonary) 
occurred 2 years after soft tissue sarcoma primary surgery in two patients; one treated by 
metastasectomy and the other by sternothoracotomy and extensive resection. Of 1017 patients 
treated at our institution for soft tissue sarcomas of the extremities, 238 were also treated for 
their first LR, with significant worsening of their prognosis. 28 To the best of our knowledge, this 
study is the first to assess the hazards of fat grafting in a restricted population affected by a rare 
and peculiar tumor type such as sarcoma. After a median time of approximately 4 years from 
cancer surgery, fat grafting was associated with a moderately low risk of LR (4.6% in 2 years), 
albeit with a CI of 20.9%. In particular, our study strengthens the positive findings about the 
possible secondary effects of fat grafts in the breast, a much-debated issue in the literature. Ten 
patients having seven different histological tumor types were treated with fat injections, the most 
common type of tumor being angiosarcoma with three cases. Only one LR was reported in a 
phyllodes tumor, but before fat grafting. Our findings therefore suggest that fat grafting –with its 
biological implications –should be considered as onco- logically safe. The number of patients 
with relapses (three out of more than 60: one distant and two local) suggests a low risk. The 
patient with the recurrent desmoid tumor had a history of multiple LRs before fat injection and 
was disease free for 2.4 months between LR and fat grafting. The subsequent LR can reasonably 
be attributed to the inherently higher local malignancy of desmoid tumors rather than to cancer 
growth stimulation by stromal cells and growth factors in the fat grafts. A recent meta-analysis 
found an overall recurrence rate of 25.1% in patients with primary disease and 46.3% in patients 
with recurrent desmoid-type fibromatosis. 29 The only discordant datum is the short interval of 3 
months from the previous surgery for LR (thigh amputation) and fat injection. In the other nine 
patients with earlier LR, fat grafting was performed 10–204 months after LR occurrence and 
treatment. Another sarcoma with high LR rates and no risk of distant metastases is 
dermatofibrosarcoma protuberans (DFSP). LRs have been found to occur between 3 and 5 years 
after resection in more than 20% of patients. 30 In our series, two of seven patients developed 
LR, but we did not find any recurrent disease in patients who had undergone fat injection 
procedures after disease-free intervals of 17 and 44 months after LR. Our study included seven 
patients affected by DFSP, two of whom with LR before fat grafting and none after. The second 
case of LR after fat injection was a 10 year-old child with Ewing’s sarcoma of the hip treated by 
primary chemotherapy, surgery, and radiotherapy. The remarkably invasive and very late-onset 
LR (168 months after surgery) occurred 24 months after the first four fat graftings and nine 
months after the last. This event is highly unexpected after complete remission. In a study by 
Bacci et al. 31 , 98.6% of LRs occurred within 10 years of primary treatment in a group of 402 
patients with nonmetastatic Ewing’s sarcoma; during a mean follow-up of 18 years, the mean 
time to relapse was 28.1 months (range, 2–240 months) and only one LR was re- ported between 
11 and 15 years. The case of this child shows similarities with the above- mentioned case report 
by Perrot et al. 25 of LR occurring13 years after primary treatment of a telangiectatic 
osteosarcoma of the humerus; LR was detected at 28 and 18 months, respectively, after the first 
and last of three fat-injection procedures. Neither our case nor Perrot’s showed any pre- dictive 
factors for LR, with wide surgical margins being obtained and multimodality therapy being given 
in both cases. When Perrot et al. subsequently investigated the correlation between fat injections 
and human osteosarcoma growth in immunodeficient mice, they found that fat injections pro- 
moted the growth of osteosarcoma cells. The mesenchymal stem cells differentiated into 
osteoblasts and adipocytes as well as muscle cells of vascular smooth muscle lineage. There is no 
evidence that adult stem cells or mesenchymal stem cells are tumorigenic per se, although 
liposarcomas contain an aggressive multipotent malignant cell population similar to adult stem 
cells. 32 The safety of lipofilling should be investigated in relation to late disease progression 
because the interaction between an adipose tissue microenvironment, adult stem cells, and tumor 
cell growth is not immediate, and if there is any tumorigenic effect, it will take months or years 
for it to be- come macroscopically evident. The connection between inflammation and 
tumorigene- sis through intrinsic and extrinsic pathways 33 could also con- tribute to the late 
onset of LR. In our case, a chronic inflammatory microenvironment generated by fat grafting 
into the tumor bed might have activated an extrinsic pathway to LR. Several lines of evidence 
indicate that inflammation is im- plicated in sarcomagenesis through the activation of the key 
transcription factors NF- κB, STAT-3, and HIF-1, which are in- volved in a complex 
inflammatory network. 34 Additional questions to investigate are whether fat injections are 
determinants in the clock-like mechanism that controls the angiogenic switch of dormant 
sarcoma cells and whether inhibitors of proinflammatory pathways are able to control the 
behavior of fat grafts in the tumor bed of resected osteosarcomas and Ewing’s sarcomas.  
 
Conclusions  
The rarity, histological heterogeneity, different age groups, and diverse anatomical sites of bone 
and soft tissue sarco- mas complicate the analysis of outcomes. In addition, basic and 
translational research into the association of the fat microenvironment, adipose-derived stem 
cells, and related growth factors is faced with the challenge of the unclear and multifarious 
etiology of sarcomas. According to our results, fat grafting seems to be a safe procedure in 
sarcoma patients, even though some caution is required. A waiting time of at least 12 months 
between the latest oncological surgery and this type of reconstructive procedure should be 
included in the treatment planning when there is a high risk of immediate relapse. A stimulatory 
role of fat injected into the tumor bed cannot be excluded in bone sarcoma even after a long 
period of remission. Our findings highlight the need for further studies with longer follow-up and 
larger series of patients from specialized cancer centers. 
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Table 1 Cancer Histology (Total: 60 tumors). 
Fibroblastic  
sarcoma  
n = 11 
Rhabdomyo  
sarcoma  
n = 6 
Liposarcoma  
 
n = 6 
Pleomorphic 
sarcoma  
n = 6 
Synovial 
sarcoma 
n = 5 
Spindle cell  
sarcoma  
n = 3 
Angio 
sarcoma 
n = 3 
Leiomyo 
sarcoma  
n = 2 
Bones 
sarcoma n = 6 
Epithelioid 
sarcoma  
n = 1 
Other tumors n 
= 6 
Embryonal 
tumors  
n = 5  
DFSP 7 
 
Myxofibro- 
sarcoma 4 
 
Embryonal 3  
 
Classic 
 variant 2 
 
Botryoid type 1 
Myxoid 4  
 
Pleomorphic 1  
 
 
Lipoma-like 1 
6 5 Classic  
variant 2  
Epithelioid  
pleomorphic  
variant 1 
3 Pleomorphic 1 
 
Classic  
variant 1 
Osteosarcoma 
2 
Ewing/PNET 4 
 
1  Malignant 
Phyllodes 2  
Ewing/PNET 2 
Aggressive 
Fibromatosis 1 
Langerhans cell 
Histiocytosis 
 
Retinoblastoma 
3  
 
Ganglioneuro 
blastoma 1  
Neuroblastoma 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2  
Patients with locoregional recurrence before lipofilling. 
Case First 
surgery 
LR (No.) Last 
surgery/ 
therapy 
Histotype Grading Site Distant 
metastasis 
Disease-
free time 
before LR 
(months) 
Disease-
free time 
from LR 
to 
lipofilling 
(months) 
Lipofilling 
Session 
(No.) 
Overall 
Follow-up 
(months) 
1 1978 5 2011 Osteosarcoma High Maxillary 
bone 
0 204 33 1 429  
2 1991 1 2002 Ewing’s 
sarcoma/PNET 
High Trunk 0 120 91 3 282 
3 2005 1 2007 Dermatofibrosarcoma Low Trunk 0 27 27 1 110 
4 1996 1 1999 Leiomyosarcoma High Breast 0 41 119 2 279 
5 2009 1 2010 Pleomorphic sarcoma High Limb 0 17 17 2 65 
6 2007 1 2008 Dermatofibrosarcoma Low Trunk 0 10 44 2 84 
 7 1982 4 2007 Aggressive 
fibromatosis 
Low Limb 0 4 3 1 325 
8 2000 2 2005 Langerhans cell 
histiocytosis 
n/a Cranio-
maxillo-
facial 
region 
0 22 60 5 179 
9 1992 1 1997 Rabdomyosarcoma  n/a Neck 0 n/a 120 10 204 
10 2004 1 2009 Malignant Phyllodes Low Breast 0 60 64 2 130 
 
 
 
 
 
 Figure 1  
Disease specific survival 
 
 
 
 
